PMV Pharmaceuticals

OrganisationROR

Trials

NCT07372625
Phase 1, Recruiting, 14 people, 28 Jan 2026

Named in competing interests

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer
Consulting or advice, Board or leadership role, 24 Sept 2026
Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer
Consulting or advice, Board or leadership role, 4 Mar 2026
Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness
Consulting or advice, Board or leadership role, 25 Nov 2025

Sources: pubmed.ncbi.nlm.nih.gov